Omnicell (OMCL) to Release Quarterly Earnings on Thursday

Omnicell (NASDAQ:OMCL) is scheduled to be issuing its quarterly earnings data before the market opens on Thursday, May 2nd. Analysts expect the company to announce earnings of ($0.08) per share for the quarter. Individual that are interested in participating in the company’s earnings conference call can do so using this link.

Omnicell (NASDAQ:OMCL) last released its earnings results on Thursday, February 8th. The company reported $0.12 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.22. Omnicell had a positive return on equity of 3.43% and a negative net margin of 1.78%. The company had revenue of $258.85 million for the quarter, compared to analysts’ expectations of $256.00 million. On average, analysts expect Omnicell to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Omnicell Stock Performance

NASDAQ OMCL opened at $27.43 on Thursday. The company has a current ratio of 2.52, a quick ratio of 2.22 and a debt-to-equity ratio of 0.48. Omnicell has a 12-month low of $25.69 and a 12-month high of $77.14. The stock has a market capitalization of $1.26 billion, a price-to-earnings ratio of -60.96 and a beta of 0.76. The business’s 50 day moving average is $27.70 and its two-hundred day moving average is $32.48.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. Barclays started coverage on Omnicell in a report on Wednesday, January 3rd. They issued an “underweight” rating and a $33.00 target price for the company. Benchmark reduced their price objective on shares of Omnicell from $42.00 to $38.00 and set a “buy” rating for the company in a research note on Friday, February 9th. Finally, Wells Fargo & Company lowered their target price on shares of Omnicell from $28.00 to $26.00 and set an “equal weight” rating on the stock in a research report on Friday, February 9th. One analyst has rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $42.20.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.